Galectin Therapeutics Inc (GALT)
3.24
-0.11
(-3.28%)
USD |
NASDAQ |
May 08, 16:00
3.23
-0.01
(-0.31%)
After-Hours: 20:00
Galectin Therapeutics Enterprise Value: 248.87M for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 08, 2024 | 248.87M |
May 07, 2024 | 255.68M |
May 06, 2024 | 263.11M |
May 03, 2024 | 255.06M |
May 02, 2024 | 256.92M |
May 01, 2024 | 264.97M |
April 30, 2024 | 265.59M |
April 29, 2024 | 271.16M |
April 26, 2024 | 261.87M |
April 25, 2024 | 264.97M |
April 24, 2024 | 251.97M |
April 23, 2024 | 257.54M |
April 22, 2024 | 237.73M |
April 19, 2024 | 256.92M |
April 18, 2024 | 257.54M |
April 17, 2024 | 257.54M |
April 16, 2024 | 258.78M |
April 15, 2024 | 290.35M |
April 12, 2024 | 294.06M |
April 11, 2024 | 308.30M |
April 10, 2024 | 284.78M |
April 09, 2024 | 292.20M |
April 08, 2024 | 279.82M |
April 05, 2024 | 279.20M |
April 04, 2024 | 234.02M |
Date | Value |
---|---|
April 03, 2024 | 224.73M |
April 02, 2024 | 203.68M |
April 01, 2024 | 199.35M |
March 28, 2024 | 196.25M |
March 27, 2024 | 197.49M |
March 26, 2024 | 195.02M |
March 25, 2024 | 192.54M |
March 22, 2024 | 199.35M |
March 21, 2024 | 199.35M |
March 20, 2024 | 184.49M |
March 19, 2024 | 178.30M |
March 18, 2024 | 180.78M |
March 15, 2024 | 175.83M |
March 14, 2024 | 170.87M |
March 13, 2024 | 170.87M |
March 12, 2024 | 170.25M |
March 11, 2024 | 172.73M |
March 08, 2024 | 174.59M |
March 07, 2024 | 177.68M |
March 06, 2024 | 177.06M |
March 05, 2024 | 175.83M |
March 04, 2024 | 171.49M |
March 01, 2024 | 167.78M |
February 29, 2024 | 169.33M |
February 28, 2024 | 165.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
40.90M
Minimum
Mar 18 2020
308.30M
Maximum
Apr 11 2024
136.78M
Average
127.74M
Median
Jun 09 2020
Enterprise Value Benchmarks
Madrigal Pharmaceuticals Inc | 3.621B |
Viking Therapeutics Inc | 7.849B |
89bio Inc | 305.80M |
Terns Pharmaceuticals Inc | 127.70M |
Enanta Pharmaceuticals Inc | -67.20M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -9.997M |
Total Expenses (Quarterly) | 9.561M |
EPS Diluted (Quarterly) | -0.16 |
Earnings Yield | -22.84% |